TABLE 1.
Clinical characteristics of included patients
| Characteristics | n = 45 |
|---|---|
| Age, years (range) | 85 (80‐94) |
| Gender, Male/Female | 10/35 |
| Smoking status | |
| Current | 11 (24) |
| Past | 28 (62) |
| Never | 6 (14) |
| Comorbidities | |
| Hypertension | 18 (40) |
| Diabetes mellitus | 5 (11) |
| COPD | 20 (44) |
| Interstitial pneumonia | 9 (20) |
| Autoimmune disease | 3 (7) |
| Clinical stage | |
| 1 | 6 (13) |
| 2 | 4 (9) |
| 3 | 17 (38) |
| 4 | 18 (40) |
| Histopathology | |
| Squamous cell carcinoma | 20 (44) |
| Adenocarcinoma | 21 (47) |
| Not otherwise specified | 4 (9) |
| Driver oncogene alteration | |
| EGFR mutation | 4 (9) |
| Performance status | |
| 2≤ | 16 (36) |
| Immune checkpoint inhibitor | |
| Nivolumab | 21 (47) |
| Pembrolizumab | 17 (38) |
| Atezolizumab | 7 (15) |
| Number of prior treatments | |
| 1≤ | 38 (84) |
Note: Data are expressed as number (%) or median (range).
Abbreviations: COPD, chronic obstructive pulmonary disease; EGFR, epidermal growth factor receptor.